← board
TECH
distress 1/10 · well-funded / low risk$71.94+0%today0% from 52w high
Revenue
$894M
Liquidity
$210M
Runway
—
Shares 1y
+1%
Price & events
+3.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
+0.2%
1W
+27.9%
1M
+38.1%
3M
+5.9%
6M
+30.9%
1Y
-4.9%
2Y
-38.0%
5Y
-6.3%
All
Overview
- Market Cap
- $11.26B
- Volume
- 471.37K
- 52 Week Range
- $43.30 – $72.12
- Total Shares
- 156.57M
- Float Shares
- 155.96M
- Short %
- 11.66%
- % Held by Insiders
- 0.31%
- % Held by Institutions
- 118.26%
- RVOL
- 0.07x
- Beta
- 1.29
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-25partnershipBio-Techne entered into a merger agreement with Merck KGaA, Darmstadt, Germany.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $70 (-3% upside) · 12 analysts
- 2026-07-09RBC CapitalOutperform → Sector Perform
- 2026-06-30BenchmarkBuy → Hold
- 2026-06-30TD CowenBuy → Hold
- 2026-06-29CitigroupBuy → Neutral
- 2026-06-26William BlairOutperform → Market Perform
- 2026-06-26BairdNeutral
Competitors
- none identified
Recent news
- 2026-07-20ETFs Investing in Bio-Techne Corporation Stocks - TradingView
- 2026-07-20What to Expect From Bio-Techne's Next Quarterly Earnings Report - Barchart.com
- 2026-07-13Bio-Techne Corp (TECH) Stock Analysis: Navigating the Biotechnology Landscape Amidst Revenue Challenges - DirectorsTalk Interviews
- 2026-07-09RBC Capital downgrades Bio-Techne stock rating on acquisition view - Investing.com
- 2026-07-08Bio-Techne Corp : RBC Cuts to Sector Perform - Moomoo
- 2026-06-26William Blair downgrades Bio-Techne stock rating on Merck acquisition - Investing.com
- 2026-06-26Deutsche Bank cuts Bio-Techne stock rating on Merck acquisition - Investing.com
- 2026-06-25S&P 500 Futures Climb in Premarket Trading; Bio-Techne, Micron Technology Lead - Barron's
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.